Advances in lyotropic liquid crystal systems for skin drug delivery

Silvestrini, Ana Vitória Pupo; Caron, Angelo Luis; Viegas, Juliana Santos Rosa; Praça, Fabíola Silva Garcia; Bentley, Maria Vitória Lopes Badra

doi:10.1080/17425247.2020.1819979

Cited by 57 publications

(32 citation statements)

References 216 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LCNPs are formed by breaking down the bulk liquid crystalline, which is a matter between liquid and solid crystalline arrays, to nanosized particles composed of amphiphilic lipids with anisotropic structures, such as inverse hexagonal and cubic mesophases ( Zeng et al, 2012 ; Silvestrini et al, 2020 ). Glycerol monooleate (monoolein, MO), a nontoxic, biodegradable amphiphilic lipid, is commonly used for the generation of LCNPs owing to its distinct property of polymorphism.…”

Section: Nanoparticlesmentioning

confidence: 99%

Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis

Qin

Dai

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated skin disorder involving hyperproliferation of the keratinocytes in the epidermis. As complex as its pathophysiology, the optimal treatment for psoriasis remains unsatisfactorily addressed. Though systemic administration of biological agents has made an impressive stride in moderate-to-severe psoriasis, a considerable portion of psoriatic conditions were left unresolved, mainly due to adverse effects from systemic drug administration or insufficient drug delivery across a highly packed stratum corneum via topical therapies. Along with the advances in nanotechnologies, the incorporation of nanomaterials as topical drug carriers opens an obvious prospect for the development of antipsoriatic topicals. Hence, this review aims to distinguish the benefits and weaknesses of individual nanostructures when applied as topical antipsoriatics in preclinical psoriatic models. In view of specific features of each nanostructure, we propose that a proper combination of distinctive nanomaterials according to the physicochemical properties of loaded drugs and clinical features of psoriatic patients is becoming a promising option that potentially drives the translation of nanomaterials from bench to bedside with improved transdermal drug delivery and consequently therapeutic effects.

show abstract

Section: Nanoparticlesmentioning

confidence: 99%

Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis

Qin

Dai

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…In vitro drug release studies have shown that the order of the cumulative drug release rate at 24 h is sonophoresis (73%) > electroporation (55%) > cold laser dialysis (54%)> MTX patch without penetration enhancement technology (45%). In the CFA-induced inflammation model of rats, the reduction rate of paw swelling diameter and the degree of pain reduction of the ultrasound-permeated MTX patch group were higher than those of the nonphysical permeable MTX patch group on day 5 and day 21 (Vaidya & Shende, 2020 ).…”

Section: Ra Transdermal Dosage Formmentioning

confidence: 99%

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

et al. 2022

View full text Add to dashboard Cite

Rheumatoid arthritis is a chronic autoimmune disease, with the features of recurrent chronic inflammation of synovial tissue, destruction of cartilage, and bone erosion, which further affects joints tissue, organs, and systems, and eventually leads to irreversible joint deformities and body dysfunction. Therapeutic drugs for rheumatoid arthritis mainly reduce inflammation through regulating inflammatory factors. Transdermal administration is gradually being applied to the treatment of rheumatoid arthritis, which can allow the drug to overcome the skin stratum corneum barrier, reduce gastrointestinal side effects, and avoid the first-pass effect, thus improving bioavailability and relieving inflammation. This paper reviewed the latest research progress of transdermal drug delivery in the treatment of rheumatoid arthritis, and discussed in detail the dosage forms such as gel (microemulsion gel, nanoemulsion gel, nanomicelle gel, sanaplastic nano-vesiclegel, ethosomal gel, transfersomal gel, nanoparticles gel), patch, drug microneedles, nanostructured lipid carrier, transfersomes, lyotropic liquid crystal, and drug loaded electrospinning nanofibers, which provide inspiration for the rich dosage forms of transdermal drug delivery systems for rheumatoid arthritis.

show abstract

“…The templated nanostructured materials are often used as drug sustained-release delivery vehicles to encapsulate drugs into their controllable channels. [9,[14][15][16] Combing the biocompatibility of GO and the controlled pore nanostructure, we designed a novel templated nanostructured GO carrier, whose well defined and uniformly distributed lamellar or hexagonal nanochannels served as reservoir for drugs. In this contribution, the nonionic surfactants polyoxyethylene (20) stearyl ether (Brij S20) and polyoxyethylene (100) stearyl ether (Brij S100) were used as the template molecules, and the lamellar or hexagonal liquid crystalline phase was formed by mixing the aqueous GO dispersion and the surfactants.…”

Section: Introductionmentioning

confidence: 99%

“…After the removal of amphiphilic surfactant which served as the templating molecules, the ordered nanochannels formed, presenting the same or complementary nanostructure of the LLC phases. The templated nanostructured materials are often used as drug sustained‐release delivery vehicles to encapsulate drugs into their controllable channels [9,14–16] …”

Section: Introductionmentioning

confidence: 99%

Preparation of Nanostructured Graphene Oxide and Its Application in Drug Loading and Sustained Release

You

Guo

et al. 2022

ChemistrySelect

View full text Add to dashboard Cite

Graphene oxide (GO) and its derivatives are considered as a promising drug carrier in tumor therapy due to their excellent biocompatibility. Here, a series of nanostructured GO with long‐range ordered lamellar or hexagonal structure were prepared by lyotropic liquid crystals (LLCs) templating strategy and used as drug carriers. The nanostructure was verified via polarized‐light optical microscopy (POM), low angle X‐ray diffraction (XRD) and transmission electron microscopy (TEM), which showed that the interlayer spacing or pore size was determined by the carbon chain length of templating molecular. 5‐fluorouracil (5‐Fu), doxorubicin (DOX) and docetaxel (DOC) which had gradually increased molecular size were chosen as model drugs, and the highly ordered nanochannels can be used as space for adsorption and diffusion of drug molecules. Ultraviolet spectrometer and simulated release test in vitro were used to determine drug loading capacity and drug release performance. The results showed that larger pore diameter/layer spacing was beneficial to the adsorption and diffusion of drug molecules, especially those with shorter molecule size. Besides, the water‐solvable DOX exhibited fast release rate than the hydrophobic 5‐Fu and DOC. The in vitro cytotoxicity assay demonstrated the good biocompatibility of both the pristine GO and the nanostructured GO.

show abstract

Advances in lyotropic liquid crystal systems for skin drug delivery

Cited by 57 publications

References 216 publications

Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis

Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

Preparation of Nanostructured Graphene Oxide and Its Application in Drug Loading and Sustained Release

Contact Info

Product

Resources

About